Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Denali Therapeutics ( (DNLI) ) has provided an update.
On January 6, 2026, Denali Therapeutics outlined its key priorities and expected milestones for 2026, positioning the year as a pivotal period as it prepares for a potential U.S. accelerated approval and commercial launch of tividenofusp alfa for Hunter syndrome, with an FDA decision due by April 5, 2026 and confirmatory data expected from the ongoing global Phase 2/3 COMPASS trial. The company also highlighted an anticipated wave of clinical readouts across its portfolio, including initial Phase 1/2 data for DNL126 in Sanfilippo syndrome Type A, patient data from the TAK-594/DNL593 frontotemporal dementia program, Phase 2b LUMA results for the LRRK2 Parkinson’s candidate BIIB122, and Phase 2 data for Sanofi-licensed eclitasertib in ulcerative colitis, alongside the initiation of first-in-human trials for multiple TV-enabled Alzheimer’s and Pompe disease therapies. Supported by roughly $873 million in cash and securities as of September 30, 2025, plus proceeds from a late-2025 equity raise and a royalty funding deal tied to future tividenofusp alfa sales, Denali signaled it has the capital to advance its clinical and commercial ambitions while reinforcing its strategy to establish leadership in transferrin receptor-enabled, blood-brain-barrier-crossing therapeutics.
The most recent analyst rating on (DNLI) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Denali Therapeutics stock, see the DNLI Stock Forecast page.
Spark’s Take on DNLI Stock
According to Spark, TipRanks’ AI Analyst, DNLI is a Neutral.
The score is held down primarily by weak financial performance (zero TTM revenue, large losses, and significant cash burn), with soft technical momentum adding pressure. Recent financing events modestly improve liquidity, but they also underscore continued external funding needs, while valuation inputs are limited by negative earnings and no dividend.
To see Spark’s full report on DNLI stock, click here.
More about Denali Therapeutics
Denali Therapeutics Inc., based in South San Francisco, is a biotechnology company focused on developing a new class of biotherapeutics that cross the blood-brain barrier using its proprietary TransportVehicle platform. The company’s pipeline targets neurodegenerative diseases, lysosomal storage disorders and other serious conditions, with candidates spanning enzymes, oligonucleotides and antibodies, and it partners with Biogen, Takeda and Sanofi on select programs while aiming to commercialize its own therapies globally.
Average Trading Volume: 1,565,290
Technical Sentiment Signal: Sell
Current Market Cap: $2.5B
Find detailed analytics on DNLI stock on TipRanks’ Stock Analysis page.